FDA warns of serious blood disorder resulting from abuse of Opana ER

October 22, 2012

FDA has warned patients of thrombotic thrombocytopenic purpura (TTP), a serious blood disorder, resulting from misuse of oxymorphone hydrochloride extended-release tablets (Opana ER, Endo).